Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the U.S. Food and Drug Administration (FDA) for its Nicardipine Hydrochloride Injection, which is indicated for short-term treatment of hypertension when oral therapy is not feasible [1] Group 1 - The approved product is Nicardipine Hydrochloride Injection, with a dosage of 25mg/10mL (2.5mg/mL) [1] - The ANDA number for the approved product is 216819 [1] - The indication for this medication is specifically for the short-term treatment of hypertension [1]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药（维权）的李前伦、灵康药业（维 权）的隋国平、海正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈 锡飞为行业唯一一个拥有博士学历的专职 ...

Group 1 - The core viewpoint of the article highlights the stock performance of Jianyou Co., which reported a slight decline in share price on August 4, 2025, closing at 11.66 yuan, down 0.02 yuan or 0.17% from the previous trading day [1] - Jianyou Co. operates in the chemical pharmaceutical sector, with its main business in pharmaceutical manufacturing, which accounted for 99.85% of its operations in 2024 [1] - The company specializes in the research, production, and sales of heparin products, including both active pharmaceutical ingredients and formulations [1] Group 2 - In the first quarter of 2025, Jianyou Co. achieved a revenue of 885 million yuan and a net profit attributable to shareholders of 84.71 million yuan [1] - As of July 31, 2025, the company had repurchased a total of 880,000 shares, representing 0.05% of its total share capital, with a total repurchase amount of 10.22 million yuan at prices ranging from 11.58 yuan to 11.66 yuan [1] - On August 4, 2025, the net outflow of main funds was 22.63 million yuan, accounting for 0.12% of the circulating market value, with a cumulative net outflow of 10.12 million yuan over the past five days, representing 0.05% of the circulating market value [1]

Group 1 - The core announcement is that Jianyou Co., Ltd. has repurchased a total of 880,000 shares as of July 31, 2025, through the Shanghai Stock Exchange trading system [1] - The repurchased shares account for 0.05% of the company's total share capital [1]

格隆汇8月4日丨健友股份(603707.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式已累计回购股份88万股，已回购股份占公司总股本的比例为0.05%，成交最低价为 11.58元/股，成交最高价为11.66元/股，支付的总金额为人民币1,022.07万元（不含交易费用及印花 税）。 ...

| | | 债券代码：113579 债券简称：健友转债 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： | 回购方案首次披露日 | 2025/4/29，由董事长唐咏群先生提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 5 月 5 | 20 | 日~2026 | 年 | 月 | 19 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 88万股 | | | | | | | 累计已回购股数占总股本比例 | 0.05% | | | | | | | 累计已回购金额 | 1,022.07万元 | | | | | | | 实际 ...

Group 1 - The company, Jianyou Co., Ltd. (SH 603707), announced on August 4 that it has repurchased a total of 880,000 shares through the Shanghai Stock Exchange, accounting for 0.05% of its total share capital [2] - The repurchase was conducted at a minimum price of 11.58 CNY per share and a maximum price of 11.66 CNY per share, with a total expenditure of 10.22 million CNY [2] - For the year 2024, the company's revenue composition indicates that 99.85% comes from the pharmaceutical manufacturing industry, while other businesses contribute 0.15% [2]

Core Insights - The article highlights the rapid development and success of the Nanjing Biopharmaceutical Valley, showcasing the approval of new drugs and the establishment of biotech companies in the region [1][2][4]. Group 1: New Drug Approvals - Nanjing Zhengxiang Pharmaceutical's new flu drug, Jike Shou (Marcelosavir), received approval from the National Medical Products Administration on July 18 [1]. - The antibody drug, Suweishitamon (Enzeshu), developed by Xiansheng Pharmaceutical, was approved just half a month earlier [1]. - The Nanjing Biopharmaceutical Valley has over 200 new drugs in development, with a total of 405 approved drugs, including six new drugs [3]. Group 2: Innovative Drug Development - Jike Shou was developed in just six years, breaking the conventional "three tens" rule of a 10-year development cycle, $1 billion investment, and a success rate below 10% [2]. - The drug demonstrated rapid efficacy, with significant symptom relief achieved in just 23.6 hours during clinical trials [2]. - The success of Zhengxiang Pharmaceutical is attributed to a team of experts returning from the San Francisco Bay Area, focusing on unmet clinical needs in oncology and infectious diseases [2]. Group 3: Company Growth and Listings - Nanjing Weilizhibo Biotechnology successfully listed on the Hong Kong Stock Exchange on July 25, following the earlier listing of Yaojie Ankang [1][5]. - Weilizhibo has developed 14 innovative drug candidates, with six in clinical stages, including the globally leading PD-L1×4-1BB dual antibody [4][5]. - The company’s rapid growth is supported by its pilot production base established in the Biopharmaceutical Valley [5]. Group 4: Ecosystem and Collaboration - The Nanjing Biopharmaceutical Valley fosters a collaborative ecosystem, integrating research, production, and application to support company growth [6][9]. - The establishment of the Nanjing Biopharmaceutical Center has facilitated technology transfer and innovation, with over 1,300 biopharmaceutical companies in the area [6][9]. - The center has partnered with over 100 research institutions and companies, significantly reducing research and development costs [7]. Group 5: Future Development and Urban Integration - The Nanjing Biopharmaceutical Valley aims to become a leading technology city, enhancing living spaces and ecological networks [11]. - Plans include the construction of scenic areas and improved infrastructure to support both innovation and quality of life for residents and professionals [11].

| | | 南京健友生化制药股份有限公司 关于子公司获得美国 FDA 依托泊苷注射液 药品生产场地转移注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （四）规 格：100 mg/5 mL, 500 mg/ 25 mL 和 1 g/50 mL （五）ANDA 号：074529 （六）申 请 人：Meitheal Pharmaceuticals, Inc. 二、药品其他相关情况 公司于近日收到美国 FDA 的通知，公司子公司 Meitheal 向美国 FDA 申报的 依托泊苷注射液，100 mg/5 mL, 500 mg/ 25 mL 和 1 g/50 mL（ANDA 号：074529） 生产场地转移至健进制药有限公司的申请已获得批准。 依托泊苷注射液参比制剂为 CORDEN PHARMA LATINA SPA 持有，于 1983 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司 Meitheal Pharmaceuticals, Inc.（以下简称"Meitheal"）于近日收到美国食品 ...

Core Viewpoint - The company announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received FDA approval for the production site transfer of Etoposide Injection in multiple dosages, which is expected to positively impact the company's operational performance [1] Group 1: FDA Approval - The FDA issued a production site transfer approval letter for Etoposide Injection (100mg/5mL, 500mg/25mL, and 1g/50mL) under ANDA number 074529 [1] - The approved production will take place at the subsidiary, Jianjin Pharmaceutical Co., Ltd. [1] Group 2: Financial Impact - The company has invested approximately 2.1561 million yuan in the research and development of Etoposide Injection [1] - The newly approved product is expected to be launched in the U.S. market soon, which may have a positive effect on the company's financial performance [1]